Emerging optical methods for surveillance of Barrett's oesophagus

Gut

Volumn 64, Issue 11, 2015, Pages 1816-1823

  Sturm, Matthew B ^a   Wang, Thomas D ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ANTIBODY; CYANINE DYE; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLUORESCEIN; FLUORESCEIN ISOTHIOCYANATE; FLUORESCENT DYE; LECTIN; METHYLENE BLUE; OSTEOPONTIN; PEPTIDE; SCATTER FACTOR RECEPTOR;

AUTOFLUORESCENCE IMAGING; BARRETT ESOPHAGUS; CANCER GROWTH; CAPSULE ENDOSCOPE; CHROMOENDOSCOPY; CONFOCAL LASER MICROSCOPY; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE ENDOSCOPE; ESOPHAGUS CANCER; ESOPHAGUS DYSPLASIA; FLUORESCENCE IMAGING; GENE EXPRESSION PROFILING; HUMAN; IN VIVO STUDY; INTERMETHOD COMPARISON; META ANALYSIS (TOPIC); MOLECULAR IMAGING; MOLECULAR MECHANICS; NARROW BAND IMAGING; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL FREQUENCY DOMAIN IMAGING; PRECANCER; PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; WHITE LIGHT ENDOSCOPY; ADENOCARCINOMA; DISEASE COURSE; ESOPHAGOSCOPY; ESOPHAGUS TUMOR; HEALTH SURVEY; PATHOLOGY; PROCEDURES;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; MOLECULAR IMAGING; OPTICAL IMAGING; POPULATION SURVEILLANCE;

EID: 84947569478     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-306706     Document Type: Review

References (87)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013. http://globocan.iarc.fr
2. American Cancer Society. Cancer facts & figures 2012. Atlanta: American Cancer Society, 2012.
3. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013;119:1149-58.
4. Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
5. Ryan AM, Duong M, Healy L, et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: Epidemiology, etiology and new targets. Cancer Epidemiol 2011;35:309-19.
6. Pohl H, Wrobel K, Bojarski C, et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol 2013;108:200-7.
7. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47:251-5.
8. De Jonge PJF, Van Blankenstein M, Grady WM, et al. Barrett's oesophagus: epidemiology, cancer risk and implications for management. Gut 2014;63:191-202.
9. Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008;168:237-49.
10. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375-83.
11. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012;61:970-6.
12. Heitmiller RF, Redmond M, Hamilton SR, Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996;224:66-71.
13. Konda VJA, Ross AS, Ferguson MK, et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol 2008;6:159-64.
14. Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006;4:566-72.
15. Picardo SL, O'Brien MP, Feighery R, et al. A Barrett's esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based registries and high risk of low grade dysplasia. Dis Esophagus 2015;28:121-6.
16. Singh S, Manickam P, Amin AV, et al. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc 2014;79:897-909.
17. Spechler SJ, Sharma P, Souza RF, et al., American Gastroenterological Association. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011;140:1084-91.
18. Evans JA, Early DS, Fukami N, et al. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 2012;76:1087-94.
19. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014;63:7-42.
20. Peters FP, Curvers WL, Rosmolen WD, et al. Surveillance history of endoscopically treated patients with early Barrett's neoplasia: nonadherence to the Seattle biopsy protocol leads to sampling error. Dis Esophagus 2008;21:475-9.
21. Abrams JA, Kapel RC, Lindberg GM, et al. Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol 2009;7:736-42.
22. Kariv R, Plesec TP, Goldblum JR, et al. The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin Gastroenterol Hepatol 2009;7:653-8.
23. Mashimo H. Subsquamous intestinal metaplasia after ablation of Barrett's esophagus: frequency and importance. Curr Opin Gastroenterol 2013;29:454-9.
24. Kwon RS, Adler DG, Chand B, et al., ASGE Technology Committee. High-resolution and high-magnification endoscopes. Gastrointest Endosc 2009;69(3 Pt 1):399-407.
25. Wo JM, Ray MB, Mayfield-Stokes S, et al. Comparison of methylene blue-directed biopsies and conventional biopsies in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a preliminary study. Gastrointest Endosc 2001;54:294-301.
26. Ragunath K, Krasner N, Raman VS, et al. A randomized, prospective cross-over trial comparing methylene blue-directed biopsy and conventional random biopsy for detecting intestinal metaplasia and dysplasia in Barrett's esophagus. Endoscopy 2003;35:998-1003.
27. Ngamruengphong S, Sharma VK, Das A. Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett's esophagus: a meta-analysis. Gastrointest Endosc 2009;69:1021-8.
28. Longcroft-Wheaton G, Duku M, Mead R, et al. Acetic acid spray is an effective tool for the endoscopic detection of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2010;8:843-7.
29. Tholoor S, Bhattacharyya R, Tsagkournis O, et al. Acetic acid chromoendoscopy in Barrett's esophagus surveillance is superior to the standardized random biopsy protocol: results from a large cohort study (with video). Gastrointest Endosc 2014;80:417-24.
30. Lambert R, Kuznetsov K, Rey J-F. Narrow-band imaging in digestive endoscopy. ScientificWorldJournal 2007;7:449-65.
31. Sharma P, Bansal A, Mathur S, et al. The utility of a novel narrow band imaging endoscopy system in patients with Barrett's esophagus. Gastrointest Endosc 2006;64:167-75.
32. Singh M, Bansal A, Curvers WL, et al. Observer agreement in the assessment of narrowband imaging system surface patterns in Barrett's esophagus: a multicenter study. Endoscopy 2011;43:745-51.
33. Sharma P, Hawes RH, Bansal A, et al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett's oesophagus: a prospective, international, randomised controlled trial. Gut 2013;62:15-21.
34. Song J, Zhang J, Wang J, et al. Meta-analysis of the effects of endoscopy with narrow band imaging in detecting dysplasia in Barrett's esophagus. Dis Esophagus, 2014. Published Online First: 24 Apr 2014. doi: 10.1111/dote.12222
35. Song L-M, Banerjee S, Desilets D, et al, ASGE Technology Committee. Autofluorescence imaging. Gastrointest Endosc 2011;73:647-50.
36. Borovicka J, Fischer J, Neuweiler J, et al. Autofluorescence endoscopy in surveillance of Barrett's esophagus: a multicenter randomized trial on diagnostic efficacy. Endoscopy 2006;38:867-72.
37. Boerwinkel DF, Holz JA, Aalders MC, et al. Third-generation autofluorescence endoscopy for the detection of early neoplasia in Barrett's esophagus: a pilot study. Dis Esophagus 2014;27:276-84.
38. Giacchino M, Bansal A, Kim RE, et al. Clinical utility and interobserver agreement of autofluorescence imaging and magnification narrow-band imaging for the evaluation of Barrett's esophagus: a prospective tandem study. Gastrointest Endosc 2013;77:711-18.
39. Boerwinkel DF, Holz JA, Kara MA, et al. Effects of autofluorescence imaging on detection and treatment of early neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2014;12:774-81.
40. Curvers WL, Herrero LA, Wallace MB, et al. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage Neoplasia in Barrett's esophagus. Gastroenterology 2010;139:1106-14.
41. Curvers WL, van Vilsteren FG, Baak LC, et al. Endoscopic trimodal imaging versus standard video endoscopy for detection of early Barrett's neoplasia: a multicenter, randomized, crossover study in general practice. Gastrointest Endosc 2011;73:195-203.
42. Lee CM, Engelbrecht CJ, Soper TD, et al. Scanning fiber endoscopy with highly flexible, 1-mm catheterscopes for wide-field, full-color imaging. J Biophotonics 2010;3:385-407.
43. Cobb MJ, Hwang JH, Upton MP, et al. Imaging of subsquamous Barrett's epithelium with ultrahigh-resolution optical coherence tomography: a histologic correlation study. Gastrointest Endosc 2010;71:223-30.
44. Isenberg G, Sivak MV Jr, Chak A, et al. Accuracy of endoscopic optical coherence tomography in the detection of dysplasia in Barrett's esophagus: a prospective, double-blinded study. Gastrointest Endosc 2005;62:825-31.
45. Evans JA, Poneros JM, Bouma BE, et al. Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol 2006;4:38-43.
46. Suter MJ, Vakoc BJ, Yachimski PS, et al. Comprehensive microscopy of the esophagus in human patients with optical frequency domain imaging. Gastrointest Endosc 2008;68:745-53.
47. Suter MJ, Gora MJ, Lauwers GY, et al. Esophageal-guided biopsy with volumetric laser endomicroscopy and laser cautery marking: a pilot clinical study. Gastrointest Endosc 2014;79:886-96.
48. Gora MJ, Sauk JS, Carruth RW, et al. Tethered capsule endomicroscopy enables less invasive imaging of gastrointestinal tract microstructure. Nat Med 2013;19:238-40.
49. Jabbour JM, Saldua MA, Bixler JN, et al. Confocal endomicroscopy: instrumentation and medical applications. Ann Biomed Eng 2012;40:378-97.
50. De Palma GD. Confocal laser endomicroscopy in the "in vivo" histological diagnosis of the gastrointestinal tract. World J Gastroenterol 2009;15:5770-5.
51. Kiesslich R, Gossner L, Goetz M, et al. In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol 2006;4:979-87.
52. Pohl H, Rosch T, Vieth M, et al. Miniprobe confocal laser microscopy for the detection of invisible neoplasia in patients with Barrett's oesophagus. Gut 2008;57:1648-53.
53. Sharma P, Meining A, Coron E, et al. 1071 Detection of Neoplastic Tissue in Barrett's Esophagus With In Vivo Probe-Based Confocal Endomicroscopy (DONT BIOPCE). Final Results of a Prospective International RCT: Image Guided Versus 4 Quadrant Random Biopsies? Gastroenterology 2010;138(5, Supplement 1):S-155.
54. Wallace M, Lauwers GY, Chen Y, et al. Miami classification for probe-based confocal laser endomicroscopy. Endoscopy 2011;43:882-91.
55. Gaddam S, Mathur SC, Singh M, et al. Novel probe-based confocal laser endomicroscopy criteria and interobserver agreement for the detection of dysplasia in Barrett's esophagus. Am J Gastroenterol 2011;106:1961-9.
56. Tofteland N, Singh M, Gaddam S, et al. Evaluation of the updated confocal laser endomicroscopy criteria for Barrett's esophagus among gastrointestinal pathologists. Dis Esophagus 2014;27:623-9.
57. Gupta A, Attar BM, Koduru P, et al. Utility of confocal laser endomicroscopy in identifying high-grade dysplasia and adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2014;26:369-77.
58. Sharma P, Meining AR, Coron E, et al. Real-time increased detection of neoplastic tissue in Barrett's esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial. Gastrointest Endosc 2011;74:465-72.
59. Canto MI, Anandasabapathy S, Brugge W, et al. In vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia: a multicenter international randomized controlled trial (with video). Gastrointest Endosc 2014;79:211-21.
60. Dulak AM, Schumacher SE, van Lieshout J, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012;72:4383-93.
61. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006;38:468-73.
62. Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut, 2006;55:1810-20.
63. Timmer MR, Sun G, Gorospe EC, et al. Predictive biomarkers for Barrett's esophagus: so near and yet so far. Dis Esophagus 2013;26:574-81.
64. Chen M, Huang J, Zhu Z, et al. Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer 2013;13:1-15.
65. Gu J, Ajani JA, Hawk ET, et al. Genome-wide catalogue of chromosomal aberrations in Barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila) 2010;3:1176-86.
66. Cronin J, McAdam E, Danikas A, et al. Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE). Am J Gastroenterol 2011;106:46-56.
67. Varghese S, Lao-Sirieix P, Fitzgerald RC. Identification and Clinical Implementation of Biomarkers for Barrett's esophagus. Gastroenterology 2012;142:435-41.
68. Tänzer M, Liebl M, Quante M. Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma. Pharmacol Ther 2013;140:133-47.
69. Mokrowiecka A, Wierzchniewska-Lawska A, Smolarz B, et al. Amplification of Her-2/neu oncogene in GERD - Barrett's metaplasia - dysplasia - adenocarcinoma sequence. Hepatogastroenterology 2013;60:1063-6.
70. Bird-Lieberman EL, Neves AA, Lao-Sirieix P, et al. Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat Med 2012;18:315-21.
71. Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929-34.
72. Miller CT, Lin L, Casper AM, et al. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2005;25:409-18.
73. Hsiung PL, Hardy J, Friedland S, et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med 2008;14:454-8.
74. Sturm MB, Joshi BP, Lu S, et al. Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results. Sci Transl Med 2013;5:184ra61.
75. Joshi BP, Miller SJ, Lee CM, et al. Multispectral endoscopic imaging of colorectal dysplasia in vivo. Gastroenterology 2012;143:1435-7.
76. Liu J, Zuo X, Li C, et al. In vivo molecular imaging of epidermal growth factor receptor in patients with colorectal neoplasia using confocal laser endomicroscopy. Cancer Lett 2013;330:200-7.
77. Atreya R, Neumann H, Neufert C, et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med 2014;20:313-18.
78. Realdon S, Dassie E, Fassan M, et al. In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. Dis Esophagus 2015;28:394-403.
79. Nakai Y, Shinoura S, Ahluwalia A, et al. Molecular imaging of epidermal growth factor-receptor and survivin in vivo in porcine esophageal and gastric mucosae using probe-based confocal laser-induced endomicroscopy: proof of concept. J Physiol Pharmacol 2012;63:303-7.
80. Lee SB, Hassan M, Fisher R, et al. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res 2008;14:3840-9.
81. Lofblom J, Feldwisch J, Tolmachev V, et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010;584:2670-80.
82. Habibollahi P, Figueiredo JL, Heidari P, et al. Optical imaging with a Cathepsin B activated probe for the enhanced detection of esophageal adenocarcinoma by dual channel fluorescent upper GI endoscopy. Theranostics 2012;2:227-34.
83. Mitsunaga M, Kosaka N, Choyke PL, et al. Fluorescence endoscopic detection of murine colitis-associated colon cancer by topically applied enzymatically rapid-activatable probe. Gut 2013;62:1179-86.
84. Sturm MB, Piraka C, Elmunzer BJ, et al. In vivo molecular imaging of Barrett's esophagus with confocal laser endomicroscopy. Gastroenterology, 2013;145:56-8.
85. Biddlestone LR, Barham CP, Wilkinson SP, et al. The histopathology of treated Barrett's esophagus: squamous reepithelialization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 1998;22:239-45.
86. Satodate H, Inoue H, Fukami N, et al. Squamous reepithelialization after circumferential endoscopic mucosal resection of superficial carcinoma arising in Barrett's esophagus. Endoscopy 2004;36:909-12.
87. Leedham SJ, Preston SL, McDonald SA, et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut 2008;57:1041-8.